Advances in diabetes for the millennium: Drug therapy of type 2 diabetes CME

Marc Rendell

Advances in diabetes for the millennium: Drug therapy of type 2 diabetes CME

Marc Rendell

Department of Medicine

Research output: Contribution to journal › Article

11 Scopus citations

Abstract

There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.

Original language	English (US)
Journal	MedGenMed Medscape General Medicine
Volume	6
Issue number	3 SUPPL.
State	Published - Dec 1 2004

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

Fingerprint Dive into the research topics of 'Advances in diabetes for the millennium: Drug therapy of type 2 diabetes CME'. Together they form a unique fingerprint.

Cite this

Rendell, M. (2004). Advances in diabetes for the millennium: Drug therapy of type 2 diabetes CME. MedGenMed Medscape General Medicine, 6(3 SUPPL.).

@article{86e1c25fdd194b939756d57dd6a21607,

title = "Advances in diabetes for the millennium: Drug therapy of type 2 diabetes CME",

abstract = "There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.",

author = "Marc Rendell",

year = "2004",

month = dec,

day = "1",

language = "English (US)",

volume = "6",

journal = "MedGenMed Medscape General Medicine",

issn = "1531-0132",

publisher = "Medscape Health Network",

number = "3 SUPPL.",

}

TY - JOUR

T1 - Advances in diabetes for the millennium

T2 - Drug therapy of type 2 diabetes CME

AU - Rendell, Marc

PY - 2004/12/1

Y1 - 2004/12/1

N2 - There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.

AB - There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.

UR - http://www.scopus.com/inward/record.url?scp=27444433718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444433718&partnerID=8YFLogxK

M3 - Article

C2 - 15647714

AN - SCOPUS:27444433718

VL - 6

JO - MedGenMed Medscape General Medicine

JF - MedGenMed Medscape General Medicine

SN - 1531-0132

IS - 3 SUPPL.

ER -